Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to December 2025, from the company's annual filing with the SEC.
| Salesyearly sales | $24.9B |
| Sales growthchange from the year before | +2.1% |
| Operating marginshare of sales left after running the business | 19.0% |
| Net marginshare of sales kept as profit | 0.0% |
| Free-cash-flow marginspare cash generated per $100 of sales | -12.3% |
| Return on invested capitalprofit made on each $100 put into the business | 4.2% |
| Return on equityprofit vs. shareholders' accounting value | 0.0% |
| Debt / equitydebt vs. shareholders' accounting value | 1.76 |
| Change in share countnegative = the company is buying back its shares | +2.6% |
2 insiders sold $2.9M (all under pre-arranged plans) on the open market.
| Santos MarleneOther | Sold (plan)Jul 22 | 158,250 shat $18.00 · $2.8M |
| Cooper Kerry WhortonDirector | Sold (plan)Jul 22 | 1,250 shat $18.00 · $23K |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy